A seminar on preclinical R&D strategic cooperation was held between Medicilon

著者：medicilon   アップロード：2020-08-20  閲読回数：

Yichang, Hubei, Aug 13, 2020 – A seminar on preclinical R&D strategic cooperation was held between Medicilon. INC and Yichang Humanwell Pharmaceutical CO.LTD. During the meeting, the two companies discussed the vision of cooperation in the future, hoping to strengthen the relationship, jointly promote the research and development process, and provide better choices for doctors and patients to cure diseases.

Yichang Humanwell is the largest research and production base of narcotic drugs in Asia. With nearly 1000 R & D personnel and excellent R & D technology and ability, Yichang Humanwell has been deeply engaged in the field of anesthesia and analgesia for many years. The company has listed remifentanil, sufentanil, as well as nabufen, hydromorphone and other domestic exclusive products. In March 2020, the company's alfentanil was approved for listing, and Yichang Renfu became the only pharmaceutical enterprise with full range of fentanyl products in China. On July 20, the company's class I new drug rimazolom benzenesulfonate for injection was approved for listing, which broke the global situation that no innovative drugs were listed in the field of anesthesia and sedation in the past 30 years, marking a milestone leap of the company's R & D strength.

上の：Medicilon MetID Services

下に：Development and analysis of inhalation drugs